Overall, skimmianine’s dual targeting of PCNA and TNF-α modulates the immune TME, highlighting its potential as a regulator of immune dynamics in breast cancer by simultaneously reversing immune suppression and mitigating tumor-promoting inflammation. The gene discussed is TNF; the disease is neoplasm.